Literature DB >> 16220857

Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin.

David Greene1.   

Abstract

Nasal inhalation of substances such as cocaine has long been linked to septal necrosis and more recently to palatal perforation. This report describes the case of a 37-year-old man who was addicted to crushed OxyContin (sustained-release oxycodone HCl) tablets and who presented with total necrosis of the septum, sinuses, and soft palate. To the best of the author's knowledge, this is the first reported case of nasal and palatal necrosis linked to nasal inhalation of crushed OxyContin, which is a relatively new form of drug abuse. The pathophysiology of drug-induced sinonasal disease and a review of the literature are also presented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220857

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  5 in total

1.  Nasopharyngeal necrosis after chronic opioid (oxycodone/acetaminophen) insufflation.

Authors:  Christopher D Rosenbaum; Katherine L Boyle; Edward W Boyer
Journal:  J Med Toxicol       Date:  2012-06

2.  Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.

Authors:  M R Lofwall; D E Moody; W B Fang; P A Nuzzo; S L Walsh
Journal:  J Clin Pharmacol       Date:  2011-05-24       Impact factor: 3.126

3.  Intranasal hydrocodone-acetaminophen abuse induced necrosis of the nasal cavity and pharynx.

Authors:  David Alexander; Keith Alexander; Joseph Valentino
Journal:  Laryngoscope       Date:  2012-09-10       Impact factor: 3.325

Review 4.  The effects of opioids on the lung.

Authors:  Joshua B Radke; Kelly P Owen; Mark E Sutter; Jonathan B Ford; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

5.  Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.

Authors:  Peter J Perrino; Salvatore V Colucci; Glen Apseloff; Stephen C Harris
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.